Interaction between lung cancer and tuberculosis in disease development and progression

doi:10.19982/j.issn.1000-6621.20240353

Abstract

Abstract:

Lung cancer is the primary cause of cancer-related mortality in China, a nation with a notably high prevalence of Mycobacterium tuberculosis (MTB) infection. Consequently, a significant population suffers from concurrent tuberculosis and lung cancer. MTB infection reshapes the host immune system, fostering a microenvironment conducive to the initiation and progression of lung cancer.Current monotherapies targeting either pulmonary tuberculosis or lung cancer exhibit limited effectiveness in managing patients with both conditions and may even lead to mutual interference. This review synthesizes evidence from PubMed and Chinese databases, offering an in-depth analysis of the mechanisms by which MTB infection facilitates lung cancer development and progression. Furthermore, it examines the overlapping clinical manifestations of these diseases, which complicate accurate diagnosis, and discusses potential strategies for integrated treatment.

Key words: Mycobacterium tuberculosis, Carcinoma, non-small-cell lung, Immunity, Literature review

CLC Number:

R52
R246.5

Liu Ruihua, Sarina , Wang Furong. Interaction between lung cancer and tuberculosis in disease development and progression[J]. Chinese Journal of Antituberculosis, 2025, 47(1): 102-111. doi: 10.19982/j.issn.1000-6621.20240353

References 107

[1]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024, 4(1):47-53. doi:10.1016/j.jncc.2024.01.006.
[2]	World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.
[3]	RABiNOVICH RM. Combined tuberculosis and primary lung cancer. Klin Med (Mosk), 1958, 36(12):57-63.
[4]	Budisan L, Zanoaga O, Braicu C, et al. Links between Infections, Lung Cancer, and the Immune System. J Int J Mol Sci, 2021, 22(17):9394. doi:10.3390/ijms22179394.
[5]	McHenry ML, Williams SM, Stein CM. Genetics and evolution of tuberculosis pathogenesis: New perspectives and approaches. J Infect Genet Evol, 2020, 81:104204. doi:10.1016/j.meegid.2020.104204.
[6]	Anastasopoulou A, Ziogas DC, Samarkos M, et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer, 2019, 7(1):239. doi:10.1186/s40425-019-0717-7. URL pmid: 31484550
[7]	Moule MG, Cirillo JD. Mycobacterium tuberculosis Dissemination Plays a Critical Role in Pathogenesis. J Front Cell Infect Microbiol, 2020, 10:65. doi:10.3389/fcimb.2020.00065.
[8]	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[9]	Luczynski P, Poulin P, Romanowski K, et al. Tuberculosis and risk of cancer: A systematic review and meta-analysis. PLoS One, 2022, 17(12):e0278661. doi:10.1371/journal.pone.0278661.
[10]	Abdeahad H, Salehi M, Yaghoubi A, et al. Previous pulmonary tuberculosis enhances the risk of lung cancer: systematic reviews and meta-analysis. J Infect Dis (Lond), 2022, 54(4):255-268. doi:10.1080/23744235.2021.2006772.
[11]	Ahmad F, Rani A, Alam A, et al. Macrophage: A Cell With Many Faces and Functions in Tuberculosis. J Front Immunol, 2022, 13:747799. doi:10.3389/fimmu.2022.747799.
[12]	Hackett EE, Charles-Messance H, O’Leary SM, et al. Mycobacterium tuberculosis Limits Host Glycolysis and IL-1β by Restriction of PFK-M via MicroRNA-21.J Cell Reports, 2020, 30(1):124-136.e124. doi:10.1016/j.celrep.2019.12.015.
[13]	Rothchild AC, Olson GS, Nemeth J, et al. Alveolar macrophages generate a noncanonical NRF2-driven transcriptional response to Mycobacterium tuberculosis in vivo. J Sci Immunol, 2019, 4(37):eaaw6693. doi:10.1126/sciimmunol.aaw6693.
[14]	Koh HM, Han N. The expression of tumor necrosis factor receptor 2 is correlated with the prognosis of cancer: a systematic review and meta-analysis. J Transl Cancer Res, 2024, 13(8):4231-4241. doi:10.21037/tcr-24-275.
[15]	Gelfo V, Romaniello D, Mazzeschi M, et al. Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies. J Int J Mol Sci, 2020, 20(17):6009. doi:10.3390/ijms21176009.
[16]	Sánchez-Ortega M, Carrera AC, Garrido A. Role of NRF2 in Lung Cancer. J Cells, 2021, 10(8):1879. doi:10.3390/cells10081879.
[17]	Pouremamali F, Pouremamali A, Dadashpour M, et al. An update of Nrf 2 activators and inhibitors in cancer prevention/promotion. J Cell Commun Signal, 2022, 20(1):100. doi:10.1186/s12964-022-00906-3.
[18]	Singh A, Daemen A, Nickles D, et al. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. J Clin Cancer Res, 2021, 27(3):877-888. doi:10.1158/1078-0432.CCR-20-1985.
[19]	Bica-Pop C, Cojocneanu-Petric R, Magdo L, et al. Overview upon miR-21 in lung cancer: focus on NSCLC. J Cell Mol Life Sci, 2018, 75(19):3539-3551. doi:10.1007/s00018-018-2877-x.
[20]	Wang W, Li X, Liu C, et al. MicroRNA-21 as a diagnostic and prognostic biomarker of lung cancer: a systematic review and meta-analysis. J Biosci Rep, 2022, 42(5):BSR20211653. doi:10.1042/BSR20211653.
[21]	Huang L, Nazarova EV, Tan S, et al. Growth of Mycobacterium tuberculosis in vivo segregates with host macrophage metabolism and ontogeny. J Exp Med, 2018, 215(4):1135-1152. doi:10.1084/jem.20172020.
[22]	Alikhanyan K, Chen Y, Kraut S, et al. Targeting alveolar macrophages shows better treatment response than deletion of interstitial macrophages in EGFR mutant lung adenocarcinoma. J Immun Inflamm Dis, 2020, 8(2):181-187. doi:10.1002/iid3.293.
[23]	Gabrusiewicz K, Li X, Wei J, et al. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L 1 expression on human monocytes. J Oncoimmunology, 2018, 7(4):e1412909. doi:10.1080/2162402X.2017.1412909.
[24]	Pisu D, Huang L, Narang V, et al. Single cell analysis of M.tuberculosis phenotype and macrophage lineages in the infected lung. J Exp Med, 2021, 218(9):e20210615. doi:10.1084/jem.20210615.
[25]	Upadhyay S, Mittal E, Philips JA. Tuberculosis and the art of macrophage manipulation. J Pathog Dis, 2018, 76(4):fty037. doi:10.1093/femspd/fty037.
[26]	Pradhan G, Shrivastva R, Mukhopadhyay S. Mycobacterial PknG Targets the Rab7l1 Signaling Pathway To Inhibit Phagosome-Lysosome Fusion. J Immunol, 2018, 201(5):1421-1433. doi:10.4049/jimmunol.1800530. URL pmid: 30037848
[27]	Wang J, Ge P, Lei Z, et al. Mycobacterium tuberculosis protein kinase G acts as an unusual ubiquitinating enzyme to impair host immunity. EMBO Rep, 2021, 22(6):e52175. doi:10.15252/embr.202052175.
[28]	Mittal E, Skowyra ML, Uwase G, et al. Mycobacterium tuberculosis Type Ⅶ Secretion System Effectors Differentially Impact the ESCRT Endomembrane Damage Response. J mBio, 2018, 9(6):e01765-e01718. doi:10.1128/mBio.01765-18.
[29]	Liu G, Pei F, Yang F, et al. Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. J Int J Mol Sci, 2017, 18(2):367. doi:10.3390/ijms18020367.
[30]	Miao CC, Hwang W, Chu LY, et al. LC3A-mediated autophagy regulates lung cancer cell plasticity. Autophagy, 2021, 18(4):921-934. doi:10.1080/15548627.2021.1964224.
[31]	Wheeler DB, Zoncu R, Root DE, et al. Identification of an oncogenic RAB protein. Science, 2015, 350(6257):211-217. doi:10.1126/science.aaa4903. URL pmid: 26338797
[32]	Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science, 2020, 368(6487):eaaw5473. doi:10.1126/science.aaw5473.
[33]	Tan Y, Li J, Zhao G, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun, 2022, 13(1):4554. doi:10.1038/s41467-022-32101-w. URL pmid: 35931676
[34]	Judd J, Abdel Karim N, Khan H, et al. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther, 2021, 20(12):2577-2584. doi:10.1158/1535-7163.MCT-21-0201. URL pmid: 34518295
[35]	Kitai H, Choi PH, Yang YC, et al. Combined inhibition of KRASG12C and mTORC 1 kinase is synergistic in non-small cell lung cancer. Nat Commun, 2024, 15(1):6076. doi:10.1038/s41467-024-50063-z.
[36]	Roy S, Ghatak D, Das P, et al. ESX secretion system: The gatekeepers of mycobacterial survivability and pathogenesis. Eur J Microbiol Immunol (Bp), 2020, 10(4):202-209. doi:10.1556/1886.2020.00028. URL pmid: 33174865
[37]	McCaffrey EF, Donato M, Keren L, et al. Author Correction: The immunoregulatory landscape of human tuberculosis granulomas. Nat Immunol, 2022, 23(5):814. doi:10.1038/s41590-022-01178-2. URL pmid: 35277696
[38]	Zheng W, Chang IC, Limberis J, et al. Mycobacterium tuberculosis resides in lysosome-poor monocyte-derived lung cells during chronic infection. PLoS Pathog, 2024, 20(5):e1012205. doi:10.1371/journal.ppat.1012205.
[39]	García-Bengoa M, Meurer M, Goethe R, et al. Role of phagocyte extracellular traps during Mycobacterium tuberculosis infections and tuberculosis disease processes. Front Microbiol, 2023, 14:983299. doi:10.3389/fmicb.2023.983299.
[40]	Liu S, Guan L, Peng C, et al. Mycobacterium tuberculosis suppresses host DNA repair to boost its intracellular survival. Cell Host Microbe, 2023, 31(11):1820-1836. e1810. doi:10.1016/j.chom.2023.09.010.
[41]	Zhai W, Wu F, Zhang Y, et al. The Immune Escape Mechanisms of Mycobacterium Tuberculosis. Int J Mol Sci, 2019, 20(2):340. doi:10.3390/ijms20020340.
[42]	Antonio N, Bønnelykke-Behrndtz ML, Ward LC, et al. The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. EMBO J, 2015, 34(17):2219-2236. doi:10.15252/embj.201490147. URL pmid: 26136213
[43]	Liu Y, Gu Y, Han Y, et al. Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. Cancer Cell, 2016, 30(2):243-256. doi:10.1016/j.ccell.2016.06.021. URL pmid: 27505671
[44]	Wang Z, Yang C, Li L, et al. Tumor-derived HMGB1 induces CD62Ldim neutrophil polarization and promotes lung metastasis in triple-negative breast cancer. Oncogenesis, 2020, 9(9):82. doi:10.1038/s41389-020-00267-x.
[45]	Bohrer AC, Castro E, Hu Z, et al. Eosinophils are part of the granulocyte response in tuberculosis and promote host resis-tance in mice. J Exp Med, 2021, 218(10):e20210469. doi:10.1084/jem.20210469.
[46]	Salina EG, Makarov V. Mycobacterium tuberculosis Dormancy: How to Fight a Hidden Danger. Microorganisms, 2022, 10(12):2334. doi:10.3390/microorganisms10122334.
[47]	Xie L, Fang J, Yu J, et al. The role of CD4⁺ T cells in tumor and chronic viral immune responses. MedComm, 2023, 4(5):e390. doi:10.1002/mco2.390.
[48]	Gern BH, Adams KN, Plumlee CR, et al. TGFβ restricts expansion, survival, and function of T cells within the tuberculous granuloma. Cell Host Microbe, 2021, 29(4):594-606.e6. doi:10.1016/j.chom.2021.02.005.
[49]	Cheng H, Ji Z, Wang Y, et al. Mycobacterium tuberculosis produces d-serine under hypoxia to limit CD8⁺ T cell-dependent immunity in mice. Nat Microbiol, 2024, 9(7):1856-1872. doi:10.1038/s41564-024-01701-1.
[50]	Ankley L, Thomas S, Olive AJ, et al. Fighting Persistence: How Chronic Infections with Mycobacterium tuberculosis Evade T Cell-Mediated Clearance and New Strategies To Defeat Them. Infect Immun, 2020, 88(7):e00916-19. doi:10.1128/IAI.00916-19.
[51]	Portal-Celhay C, Tufariello JM, Srivastava S, et al. Mycobacterium tuberculosis EsxH inhibits ESCRT-dependent CD4⁺ T-cell activation. Nat Microbiol, 2016, 2:16232. doi:10.1038/nmicrobiol.2016.232. URL pmid: 27918526
[52]	Carpenter SM, Nunes-Alves C, Booty MG, et al. A Higher Activation Threshold of Memory CD8⁺ T Cells Has a Fitness Cost That Is Modified by TCR Affinity during Tuberculosis. PLoS Pathog, 2016, 12(1):e1005380. doi:10.1371/journal.ppat.1005380.
[53]	Gallegos AM, Xiong H, Leiner IM, et al. Control of T cell antigen reactivity via programmed TCR downregulation. Nat Immunol, 2016, 17(4):379-386. doi:10.1038/ni.3386. URL pmid: 26901151
[54]	Jasenosky LD, Scriba TJ, Hanekom WA, et al. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev, 2015, 264(1):74-87. doi:10.1111/imr.12274. URL pmid: 25703553
[55]	Athman JJ, Sande OJ, Groft SG, et al. Mycobacterium tuberculosis Membrane Vesicles Inhibit T Cell Activation. J Immunol, 2017, 198(5):2028-2037. doi:10.4049/jimmunol.1601199.
[56]	Liu R, Zhao Y, Su S, et al. Unveiling cancer dormancy: Intrinsic mechanisms and extrinsic forces. Cancer Lett, 2024, 591:216899. doi:10.1016/j.canlet.2024.216899.
[57]	Flores-Guzmán F, Utikal J, Umansky V. Dormant tumor cells interact with memory CD8⁺ T cells in RET transgenic mouse melanoma model. Cancer Lett, 2020, 474:74-81. doi:10.1016/j.canlet.2020.01.016. URL pmid: 31962142
[58]	Goddard ET, Linde MH, Srivastava S, et al. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell, 2024, 42(1):119-134.e112. doi:10.1016/j.ccell.2023.12.011. URL pmid: 38194912
[59]	Tallón de Lara P, Castañón H, Vermeer M, et al. CD39⁺PD-1⁺CD8⁺ T cells mediate metastatic dormancy in breast cancer. Nat Commun, 2021, 12(1):769. doi:10.1038/s41467-021-21045-2.
[60]	Giarratana AO, Prendergast CM, Salvatore MM, et al. TGF-β signaling: critical nexus of fibrogenesis and cancer. Transl Med, 2024, 22(1):594. doi:10.1186/s12967-024-05411-4.
[61]	Porter JC, Ganeshan B, Win T, et al. ¹⁸FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases. Nucl Med, 2024, 65(4):617-622. doi:10.2967/jnumed.123.266445.
[62]	Teo AKJ, MacLean EL, Fox GJ. Subclinical tuberculosis: a meta-analysis of prevalence and scoping review of definitions, prevalence and clinical characteristics. Eur Respir Rev, 2024, 33(172):230208. doi:10.1183/16000617.0208-2023.
[63]	Jarzebska N, Karetnikova ES, Markov AG, et al. Scarred Lung. An Update on Radiation-Induced Pulmonary Fibrosis. Front Med (Lausanne), 2021, 7:585756. doi:10.3389/fmed.2020.585756.
[64]	Maranchick NF, Kwara A, Peloquin CA. Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics. Expert Rev Clin Pharmacol, 2024, 17(7):537-547. doi:10.1080/17512433.2024.2317954.
[65]	Park J, Hsueh PC, Li Z, et al. Microenvironment-driven metabolic adaptations guiding CD8⁺ T cell anti-tumor immunity. Immunity, 2023, 56(1):32-42. doi:10.1016/j.immuni.2022.12.008.
[66]	Lafta HA, AbdulHussein AH, Al-Shalah SAJ, et al. Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products. Curr Top Med Chem, 2023, 23(12):1104-1122. doi:10.2174/1568026623666230201145909. URL pmid: 36722486
[67]	Wang F, Yang M, Luo W, et al. Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer. Natl Cancer Cent, 2022, 2(4):243-262. doi:10.1016/j.jncc.2022.10.002.
[68]	Wu Q, Liu Z, Gao Z, et al. KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8⁺ T-cell-dependent antitumor immunity. Theranostics, 2023, 13(4):1381-1400. doi:10.7150/thno.82182.
[69]	Lacher SB, Dörr J, de Almeida GP, et al. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8⁺ T cells. Nature, 2024, 629(8011):417-425. doi:10.1038/s41586-024-07254-x.
[70]	Fang W, Zhou T, Shi H, et al. Progranulin induces immune escape in breast cancer via up-regulating PD-L 1 expression on tumor-associated macrophages (TAMs) and promoting CD8⁺ T cell exclusion. J Exp Clin Cancer Res, 2021, 40(1):4. doi:10.1186/s13046-020-01786-6.
[71]	Qin R, Zhao C, Wang CJ, et al. Tryptophan potentiates CD8⁺T cells against cancer cells by TRIP 12 tryptophanylation and surface PD-1 downregulation. J Immunother Cancer, 2021, 9(7):e002840. doi:10.1136/jitc-2021-002840.
[72]	Cardona PJ. Pathogenesis of tuberculosis and other mycobacteriosis. Enferm Infecc Microbiol Clin (Engl Ed), 2018, 36(1):38-46. doi:10.1016/j.eimc.2017.10.015.
[73]	Jang HJ, Lee HS, Yu W, et al. Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment. Cancer Res, 2022, 82(14):2593-2609. doi:10.1158/0008-5472.CAN-21-3506.
[74]	Soldevilla P, Vilaplana C, Cardona PJ. Mouse Models for Mycobacterium tuberculosis Pathogenesis: Show and Do Not Tell. Pathogens, 2022, 12(1):49. doi:10.3390/pathogens12010049.
[75]	Hunter L, Ruedas-Torres I, Agulló-Ros I, et al. Comparative pathology of experimental pulmonary tuberculosis in animal models. Front Vet Sci, 2023, 10:1264833. doi:10.3389/fvets.2023.1264833.
[76]	Bhatt M, Kant S, Bhaskar R. Pulmonary tuberculosis as differential diagnosis of lung cancer. South Asian J Cancer, 2012, 1(1):36-42. doi:10.4103/2278-330X.96507. URL pmid: 24455507
[77]	Shu CC, Chang SC, Lai YC, et al. Factors for the Early Revision of Misdiagnosed Tuberculosis to Lung Cancer: A Multicenter Study in A Tuberculosis-Prevalent Area. J Clin Med, 2019, 8(5):700. doi:10.3390/jcm8050700.
[78]	温立旻, 侯代伦. 肺结核合并肺癌影像学评估方法现状及进展. 中国防痨杂志, 2023, 45(6): 620-624. doi:10.19982/j.issn.1000-6621.20230045.
[79]	Zeng L Ma, Qu M, et al. Immunogenicity and protective efficacy of Ag85A and truncation of PstS 1 fusion protein vaccines against tuberculosis. Heliyon, 2024, 10(5):e27034. doi:10.1016/j.heliyon.2024.e27034.
[80]	赵爱华, 徐苗, 郑素华, 等. 针对世界卫生组织对卡介苗两次文件立场观点差异的探讨. 中国防痨杂志, 2016, 38(2):87-89. doi:10.3969/j.issn.1000-6621.2016.02.002.
[81]	Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature, 2020, 577(7788):95-102. doi:10.1038/s41586-019-1817-8.
[82]	Lamm DL, Morales A. A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment. Vaccine, 2021, 39(50):7308-7318. doi:10.1016/j.vaccine.2021.08.026. URL pmid: 34417051
[83]	Cardillo F, Bonfim M, da Silva Vasconcelos Sousa P, et al. Bacillus Calmette-Guérin Immunotherapy for Cancer. Vaccines(Basel), 2021, 9(5):439. doi:10.3390/vaccines9050439.
[84]	Jallad S, Thomas P, Newport MJ, et al. Baseline Cytokine Profiles of Tuberculin-Specific CD4⁺ T Cells in Non-Muscle-Invasive Bladder Cancer May Predict Outcomes of BCG Immunotherapy. Cancer Immunol Res, 2018, 6(10):1212-1219. doi:10.1158/2326-6066.CIR-18-0046. URL pmid: 30120103
[85]	Delahaye JL, Gern BH, Cohen SB, et al. Cutting Edge: Bacillus Calmette-Guérin-Induced T Cells Shape Mycobacterium tuberculosis Infection before Reducing the Bacterial Burden. J Immunol, 2019, 203(4):807-812. doi:10.4049/jimmunol.1900108. URL pmid: 31308091
[86]	周奉, 李同心, 杨松, 等. 结核病短程治疗方案的研究进展. 中国防痨杂志, 2023, 5(3):311-317. doi:10.19982/j.issn.1000-6621.20220447.
[87]	Pi J, Chen D, Wang J, et al. Macrophage targeted graphene oxide nanosystem synergize antibiotic killing and host immune defense for Tuberculosis Therapy. Pharmacol Res, 2024, 208:107379. doi:10.1016/j.phrs.2024.107379.
[88]	Gap-Gaupool B, Glenn SM, Milburn E, et al. Nitric oxide induces the distinct invisibility phenotype of Mycobacterium tuberculosis. Commun Biol, 2024, 7(1):1206. doi:10.1038/s42003-024-06912-0. URL pmid: 39342050
[89]	Rao Muvva J, Ahmed S, Rekha RS, et al. Immunomodulatory Agents Combat Multidrug-Resistant Tuberculosis by Improving Antimicrobial Immunity. Infect Dis, 2021, 224(2):332-344. doi:10.1093/infdis/jiab100.
[90]	Campos PC, Gomes MTR, Marinho FAV, et al. Brucella abortus nitric oxide metabolite regulates inflammasome activation and IL-1β secretion in murine macrophages. Eur J Immunol, 2019, 49(7):1023-1037. doi:10.1002/eji.201848016. URL pmid: 30919410
[91]	Nafiz TN, Sankar P, Mishra LK, et al. Differential requirement of formyl peptide receptor 1 in macrophages and neutrophils in the host defense against Mycobacterium tuberculosis Infection. Sci Rep, 2024, 14(1):23595. doi:10.1038/s41598-024-71180-1.
[92]	Miranda KM, Ridnour LA, McGinity CL, et al. Nitric Oxide and Cancer: When to Give and When to Take Away?. Inorg Chem, 2021, 60(21):15941-15947. doi:10.1021/acs.inorgchem.1c02434. URL pmid: 34694129
[93]	Mintz J, Vedenko A, Rosete O, et al. Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics. Vaccines, 2021, 9(2):94. doi:10.3390/vaccines9020094.
[94]	Gobelli D, Serrano-Lorenzo P, Esteban-Amo MJ, et al. The mitochondrial succinate dehydrogenase complex controls the STAT3-IL-10 pathway in inflammatory macrophages. Science, 2023, 26(8):107473. doi:10.1016/j.isci.2023.107473.
[95]	Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol, 2018, 15(4):234-248. doi:10.1038/nrclinonc.2018.8. URL pmid: 29405201
[96]	Emam AM, Dahal A, Singh SS, et al. Quinazoline-tethered hydrazone: A versatile scaffold toward dual anti-TB and EGFR inhibition activities in NSCLC. Arch Pharm (Weinheim), 2021, 345(12):e2100281. doi:10.1002/ardp.202100281.
[97]	Ye MF, Su S, Huang ZH, et al. Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis. Ann Transl Med, 2020, 8(18):1143. doi:10.21037/atm-20-5964.
[98]	Chai M, Shi Q. The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis. BMC Cancer, 2020, 20(1):1121. doi:10.1186/s12885-020-07622-6. URL pmid: 33213414
[99]	Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol, 2021, 16:223-249. doi:10.1146/annurev-pathol-042020-042741. URL pmid: 33197221
[100]	Langan EA, Graetz V, Allerheiligen J, et al. Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. Lancet Oncol, 2020, 21(1): e55-e65. doi:10.1016/S1470- 2045(19)30674-6.
[101]	Lin C, Xu G, Gao S, et al. Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review. Front Immunol, 2023, 14:1162190. doi:10.3389/fimmu.2023.1162190.
[102]	Chen HW, Kuo YW, Chen CY, et al. Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy. Oncologist, 2024, 29(4):e498-e506. doi:10.1093/oncolo/oyad340.
[103]	Zaemes J, Kim C. Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature. Eur J Cancer, 2020, 132:168-175. doi:10.1016/j.ejca.2020.03.015. URL pmid: 32375103
[104]	Sirgiovanni M, Hinterleitner C, Horger M, et al. Long-term remission of small cell lung cancer after reactivation of tuberculosis following immune-checkpoint blockade: A case report. Thoracic Cancer, 2021, 12(5):699-702. doi:10.1111/1759-7714.13821. URL pmid: 33458956
[105]	Doz-Deblauwe E, Bounab B, Carreras F, et al. Dual neutrophil subsets exacerbate or suppress inflammation in tuberculosis via IL-1β or PD-L1. Life Sci Alliance, 2024, 7(7):e202402623. doi:10.26508/lsa.202402623.
[106]	Yu Z, Xu C, Song B, et al. Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances. Transl Med, 2023, 21(1):708. doi:10.1186/s12967-023-04554-0.
[107]	廉娟雯, 许家玲, 华涛, 等. 恶性肿瘤继发结核病患者的临床特征及相关因素分析. 中国防痨杂志, 2019, (3): 254-259. doi:10.3969/j.issn.1000-6621.2019.03.003.